Panacea-ml

Company Overview

Snapshot

Founded in August 2022, Panacea-ml operates with 1–10 employees. The company secured its Pre-Seed funding in November 2022, with Sanara Ventures leading the round. This funding event underscores the early investor confidence in Panacea-ml's innovative approach to clinical trial optimization.

Business overview

Panacea-ml, a spin-out from Ben Gurion University, is dedicated to transforming clinical development through its Explainable AI platform. The company's core technology addresses critical issues in clinical trials, such as patient population heterogeneity and suboptimal trial design, which contribute to significant failures and financial waste in pharmaceutical R&D. Panacea-ml’s SaaS platform leverages proprietary explainable AI and causal discovery theory to provide predictive insights, aiming to de-risk, accelerate, and optimize trial designs. It serves the data analytics and design segment of the clinical trial market, with a focus on high-failure areas like neurology and immuno-metabolic diseases, operating within the Health Tech & Life Sciences sector.

Strategic signal

In July 2024, Panacea-ml became the first Israeli startup to graduate from the PharmStars accelerator program. This achievement signals strong validation of Panacea-ml's technology and business model within the pharmaceutical industry, indicating its readiness for broader market engagement and potential for strategic partnerships. For investors, this highlights the company's progress in gaining recognition and support from a pharma-focused accelerator, suggesting a positive trajectory for its market penetration and adoption.

Company Intelligence Q&A

What is Panacea-ml's primary focus?

Panacea-ml focuses on disrupting clinical development by providing an Explainable AI platform designed to streamline clinical trial design and improve success rates.

When was Panacea-ml founded?

Panacea-ml was founded in August 2022.

What was a significant recent achievement for Panacea-ml?

In July 2024, Panacea-ml graduated from the PharmStars accelerator program, becoming the first Israeli startup to do so.

Which organization provided early support to Panacea-ml?

In November 2022, Panacea-ml received Pre-Seed funding from Sanara Ventures and the Israel Innovation Authority.

What problem does Panacea-ml's technology address in clinical trials?

Panacea-ml's technology addresses patient population heterogeneity, poor trial design, and limitations of biostatistics, which are major causes of clinical trial failures.